About this content About Josh Lamb After graduating from the University of Kent in the summer of 2022 with a degree in History, Josh joined Proactive later that year as a journalist in the UK editorial team. Josh has reported on a range of areas whilst at Proactive, including energy companies during a time of global crisis, aviation and airlines as the sector recovers from the pandemic, as well as covering economic, social and governance issues. Read more About the publisher Proactive financial news and onl ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style Scores? ...

The specter of an activist investor looms over the company.Tuesday was a fairly eventful news day for U.S. pharmaceutical sector company Pfizer (PFE -1.39%). It reported third-quarter earnings and updated investors about its relationship with an activist investor in its ranks. Neither of these occurrences impressed the market, however, and the company's share price dipped by more than 1%. That was on a day when the S&P 500 index closed in the black, albeit modestly at 0.2%.Strong growth and twin beats weren ...

In a Tuesday interview with CNBC's Jim Cramer, Pfizer CEO Albert Bourla struck a positive tone about activist investor Starboard Value, saying he agreed with some of its criticisms, but maintained that the company is headed in a good direction. "I agree that the total shareholder return right now is very poor. Why is that? Because we had a significant drop last year," he said. "I think we are doing a lot of changes. But if Starboard, and anybody else for that matter, have good ideas, I will certainly discus ...

Third Quarter 2024 Earnings Teleconference 1 October 29, 2024 Introduction Francesca DeMartino Chief Investor Relations Officer, Senior Vice President Third Quarter 2024 Earnings 2 Forward-Looking Statements and Non-GAAP Financial Information • Our discussions during this conference call will include forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We include forward-loo ...

Financial Data and Key Metrics Changes - Total company revenues for Q3 2024 were $17.7 billion, representing a 32% operational growth year-over-year [41] - Adjusted diluted earnings per share (EPS) was $1.06, benefiting from top-line performance and efficient operating structure [48] - The company raised its full year 2024 revenue guidance by $1.5 billion, now expecting revenues in the range of $61 billion to $64 billion [54] Business Line Data and Key Metrics Changes - Oncology business experienced a 31% year-over-year growth, driven by strong demand for products like XTANDI and TALZENNA [9][10] - Non-COVID product revenues were $13.6 billion, reflecting a 14% operational year-over-year growth [42] - The VYNDAQEL family of products saw a 63% operational growth in Q3, attributed to expanding the healthcare provider base [36] Market Data and Key Metrics Changes - In the U.S., Pfizer became the third largest biopharma company in oncology by revenue through the first half of 2024 [9] - Prevnar20 achieved 83% market share in pediatric and 97% in adults in the U.S. [31] - ABRYSVO's market share exceeded 50% for the quarter, with a significant increase in vaccinations [33] Company Strategy and Development Direction - Pfizer is focused on executing a 5-point plan aimed at creating shareholder value, which includes enhancing operational efficiency and expanding its product pipeline [62] - The company is prioritizing scientific leadership and addressing significant unmet patient needs through its pipeline advancements [15][19] - Pfizer aims to maintain and grow its dividend while strategically deploying capital for long-term value creation [50] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver on financial commitments and create long-term shareholder value [57] - The company acknowledged challenges in total shareholder return but believes it is on the right path to improve [60] - Management highlighted the importance of ongoing cost-saving programs to enhance operating leverage over time [57] Other Important Information - Pfizer's COVID-19 products, including PAXLOVID and COMIRNATY, contributed significantly to revenue, with PAXLOVID generating $2.7 billion [41] - The company is advancing multiple candidates in its pipeline, including a new vaccine against Lyme disease and treatments for various cancers [22][24] Q&A Session Summary Question: Insights on the obesity pipeline and market strategy - Management indicated that danuglipron is expected to be the second oral GLP-1 treatment to market, with a focus on capturing market share [64][66] Question: Details on the fensegrumab program in cachexia - Management stated that initial registration will likely come from endpoints similar to Phase II studies, with a focus on improving patient performance [70][72] Question: Shareholder engagement and capital deployment - Management emphasized the importance of ongoing engagement with shareholders and the evaluation of business development opportunities [81][90] Question: Updates on Seagen integration and performance - The integration of Seagen is progressing well, with significant revenue contributions and successful execution on the pipeline [98][99]

On October 29, 2024, Pfizer (NYSE: PFE ) reported financial results for the third quarter of 2024 , which exceeded Wall Street analysts' expectations and also pleased me with the progress made in recent months. With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, technology, and pharmaceuti ...

Key TakeawaysPfizer beat third-quarter profit and sales forecasts and raised its guidance on strong sales of its COVID-19 treatment.However, shares declined as the results may have put a damper on possible changes to the company demanded by activist investor Starboard Value.CEO Albert Bourla expressed confidence in the way Pfizer is executing its strategy. Shares of Pfizer (PFE) fell Tuesday as a strong earnings report is seen as likely to limit activist investor Starboard Value from driving major changes a ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Pfizer (PFE) reported third-quarter 2024 adjusted earnings per share of $1.06, which crushed the Zacks Consensus Estimate of 64 cents per share. The company had recorded an adjusted loss of 17 cents per share in the year-ago quarter. Revenues came in at $17.7 billion, up 31% from the year-ago quarter on a reported basis, reflecting an operational increase of 32% and a negative currency impact of 1%. Total revenues significantly beat the Zacks Consensus Estimate of $15.19 billion. Higher sales of Pfizer's ke ...